Akums Drugs and Pharmaceuticals has received the Securities and Exchange Board of India (SEBI) go-ahead to raise funds through initial public offering (IPO). The initial share-sale is a combination of fresh issue of equity shares worth Rs 680 crore and an offer-for-sale (OFS) of 1.86 crore shares by promoters and an existing investor. The equity shares of the company will be listed on the BSE and NSE.
Proceeds from the fresh issue will be used to repay debt, fund working capital requirements of the company, pursue inorganic growth initiatives through acquisition and for general corporate purposes. ICICI Securities, Axis Capital, Citigroup Global Markets India and Ambit are the running lead managers to the issue.
The company is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.80 |
| Dr. Reddys Lab | 1328.05 |
| Cipla | 1288.80 |
| Zydus Lifesciences | 930.20 |
| Lupin | 2269.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: